533 related articles for article (PubMed ID: 38113005)
1. Polycomb Repressive Complex 2 in Oncology.
Guo Y; Yu Y; Wang GG
Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005
[TBL] [Abstract][Full Text] [Related]
2. The role of EZH1 and EZH2 in development and cancer.
Lee SH; Li Y; Kim H; Eum S; Park K; Lee CH
BMB Rep; 2022 Dec; 55(12):595-601. PubMed ID: 36476271
[TBL] [Abstract][Full Text] [Related]
3. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
Mu W; Starmer J; Yee D; Magnuson T
Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
[TBL] [Abstract][Full Text] [Related]
4. Regulation of histone methylation by automethylation of PRC2.
Wang X; Long Y; Paucek RD; Gooding AR; Lee T; Burdorf RM; Cech TR
Genes Dev; 2019 Oct; 33(19-20):1416-1427. PubMed ID: 31488576
[TBL] [Abstract][Full Text] [Related]
5. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition.
Romero P; Richart L; Aflaki S; Petitalot A; Burton M; Michaud A; Masliah-Planchon J; Kuhnowski F; Le Cam S; Baliñas-Gavira C; Méaudre C; Luscan A; Hamza A; Legoix P; Vincent-Salomon A; Wassef M; Holoch D; Margueron R
Nat Commun; 2024 Apr; 15(1):3452. PubMed ID: 38658543
[TBL] [Abstract][Full Text] [Related]
6. Dissecting the role of H3K27 acetylation and methylation in PRC2 mediated control of cellular identity.
Lavarone E; Barbieri CM; Pasini D
Nat Commun; 2019 Apr; 10(1):1679. PubMed ID: 30976011
[TBL] [Abstract][Full Text] [Related]
7. Polycomb repressive complex 2 in an autoinhibited state.
Bratkowski M; Yang X; Liu X
J Biol Chem; 2017 Aug; 292(32):13323-13332. PubMed ID: 28607149
[TBL] [Abstract][Full Text] [Related]
8. The roles of EZH2 in cancer and its inhibitors.
Liu Y; Yang Q
Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
[TBL] [Abstract][Full Text] [Related]
9. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
10. Jarid2 Methylation via the PRC2 Complex Regulates H3K27me3 Deposition during Cell Differentiation.
Sanulli S; Justin N; Teissandier A; Ancelin K; Portoso M; Caron M; Michaud A; Lombard B; da Rocha ST; Offer J; Loew D; Servant N; Wassef M; Burlina F; Gamblin SJ; Heard E; Margueron R
Mol Cell; 2015 Mar; 57(5):769-783. PubMed ID: 25620564
[TBL] [Abstract][Full Text] [Related]
11. Loss of Ezh2 function remodels the DNA replication initiation landscape.
Prorok P; Forouzanfar F; Murugarren N; Peiffer I; Charton R; Akerman I; Méchali M
Cell Rep; 2023 Apr; 42(4):112280. PubMed ID: 36995935
[TBL] [Abstract][Full Text] [Related]
12. The noncanonical role of EZH2 in cancer.
Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
[TBL] [Abstract][Full Text] [Related]
13. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
[TBL] [Abstract][Full Text] [Related]
14. Distinct Stimulatory Mechanisms Regulate the Catalytic Activity of Polycomb Repressive Complex 2.
Lee CH; Holder M; Grau D; Saldaña-Meyer R; Yu JR; Ganai RA; Zhang J; Wang M; LeRoy G; Dobenecker MW; Reinberg D; Armache KJ
Mol Cell; 2018 May; 70(3):435-448.e5. PubMed ID: 29681498
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic regulation of enhancer of zeste homolog 2 (EZH2) -Yin Yang 1 (YY1) axis in cancer.
Chandnani N; Gupta I; Thakkar V; Sarkar K
Pathol Res Pract; 2023 Nov; 251():154885. PubMed ID: 37862922
[TBL] [Abstract][Full Text] [Related]
16. The H3K36me2 Methyltransferase Nsd1 Demarcates PRC2-Mediated H3K27me2 and H3K27me3 Domains in Embryonic Stem Cells.
Streubel G; Watson A; Jammula SG; Scelfo A; Fitzpatrick DJ; Oliviero G; McCole R; Conway E; Glancy E; Negri GL; Dillon E; Wynne K; Pasini D; Krogan NJ; Bracken AP; Cagney G
Mol Cell; 2018 Apr; 70(2):371-379.e5. PubMed ID: 29606589
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2.
Justin N; Zhang Y; Tarricone C; Martin SR; Chen S; Underwood E; De Marco V; Haire LF; Walker PA; Reinberg D; Wilson JR; Gamblin SJ
Nat Commun; 2016 Apr; 7():11316. PubMed ID: 27121947
[TBL] [Abstract][Full Text] [Related]
18. Full methylation of H3K27 by PRC2 is dispensable for initial embryoid body formation but required to maintain differentiated cell identity.
Miller SA; Damle M; Kim J; Kingston RE
Development; 2021 Apr; 148(7):. PubMed ID: 33688077
[TBL] [Abstract][Full Text] [Related]
19. A model for transmission of the H3K27me3 epigenetic mark.
Hansen KH; Bracken AP; Pasini D; Dietrich N; Gehani SS; Monrad A; Rappsilber J; Lerdrup M; Helin K
Nat Cell Biol; 2008 Nov; 10(11):1291-300. PubMed ID: 18931660
[TBL] [Abstract][Full Text] [Related]
20. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]